SenoRx, an Irvine, CA–based manufacturer of minimally invasive medical devices for breast cancer, has been acquired by medical device powerhouse C. R. Bard for about $213 million. The transaction is expected to close during the third quarter of 2010.

"Our agreement with Bard represents an attractive valuation for SenoRx shareholders, and as an all cash offer, provides liquidity for shareholders," says John Buhler, SenoRx's president and CEO. "We believe the merger represents a great opportunity for the combined companies to create product leadership by offering a broader range of high-quality breast care products to our customers."